Quanta Raises $245M In Series D Funding

Quanta Dialysis Technologies Ltd, a medical technology company focused on dialysis care, has raised $245 million in Series D funding. The round was led by Glenview Capital and Novo Holdings, with participation from several other investors, including BlackRock, Eldridge, and Sands Capital. The company plans to use the funds to expand its global operations, particularly in the United States, where its SC+ hemodialysis system has received FDA clearance. The patented technology behind SC+ is based on a design innovation that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The company also plans to invest in infrastructure to scale up manufacturing, sales, and customer service functions.

Quanta Dialysis Secures $245 Million in Series D Funding to Expand Global Operations

Quanta Dialysis Technologies Ltd is an Alcester, England, and Beverly, MA-based medical technology company focusing dialysis care, raised $245m in Series D funding.  The company has developed a portable hemodialysis system SC+, which is an hemodialysis system designed to provide flexibility in the delivery of life sustaining dialysis treatments. In the US, SC+ is FDA cleared for use in acute and chronic care facilities, and in the UK, it is CE marked, where it has been used to treat patients across a range of care settings, from the ICU and the clinic to the home.

Quanta Dialysis Technologies Ltd is a medical technology company focusing dialysis care.

4 years ago

Quanta Dialysis Secures $245 Million in Series D Funding to Expand Global Operations

ProblemHealthcare

Solution

Covered on